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ACLT changes the biomechanical properties of articular cartilage more
than cartilage thickness although it seems that three months after ACLT,
cartilage thickness is less than control group. On the other hand, in
both femur and tibia cartilage seems to become thicker following LPLT;
however, none of these changes is statictically signiﬁcant.
Apparently, destructive effects of ACLT are more pronounced on tibial
cartilage. 12 weeks after ACLT, tibial cartilage strength and young
modulus decreased signiﬁcantly, although 10 seassions of LPT reversed
this process completely. Same trend was observed in femural cartilage
but these changes were not statistically signiﬁcant.
Conclusions: Following ACLT articular cartilage softens and its strength
decreases. It seems that therapeutic laser can help cartilage to resume
its original characteristics.
Table 1.
Fig. 1.
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MODULATING MAPK SIGNALING CAN ATTENUATE THE SEVERITY
OF OSTEOARTHRITIS
Y. Xiao, I. Prasadam, R. Crawford. Queensland Univ. of Technology,
Brisbane, Australia
Purpose: Osteoarthritis (OA) is the most common musculoskeletal
disorder and represents a major health burden to society. OA is associated
with the irreversible degeneration of articular cartilage. Notably, in
this condition, articular cartilage chondrocytes undergo phenotypic and
gene expression changes that are reminiscent of their hypertrophic
differentiation in the growth plate during skeletal development. Also, the
adjacent subchondral bone shows signs of abnormal mineral density and
enhanced production of bone turnover markers, indicative of osteoblast
dysfunction. Our previous study ﬁndings suggest that Extracellular
signal-regulated kinases (ERK) signaling is activated in both in OA
subchondral bone and cartilage. The present study is a follow up of
our previous ﬁndings to identify whether the pharmacological inhibition
ERK signaling pathway slows down the progression of OA.
Methods: We developed three different types of OA rat models:
Menisectomy (MSX) induced OA, Anterior cruciate ligament transaction
(ACLT) induced OA and Mono-ido-acetate (MIA) induced OA to test
whether U0126, a MAPK-ERK1/2 pathway inhibitor shows any protective
effects towards OA cartilage degeneration and subchondral bone changes.
The cause of disease occurrence is different in the above models;
therefore the obtained data will show how the drug is acting in different
types of OA conditions. From day 7 post-surgery treatment groups were
given an intra-articular injection of ERK1/2 inhibitor (UO126) every
2 days at a concentration of 0.5 mM in 50ml using 30G needle for
8 weeks. The control group received same volume of vehicle alone
(saline+ DMSO) without administration drug. At the end of each time
point rats were euthanized and knee joints were parafﬁn embedded.
Serial 5mm sections obtained at 100mm intervals from the non weight
bearing region and weight-bearing region of each knee joint were
stained with safranin O-fast green, Type 10 collagen (COL10), runt-related
transcription factor-2 (RUNX2) and a disintegrin and metalloproteinase
with thrombospondin type 1 motif-5 (ADAMTS5). OA severity in the
tibial plateau was evaluated according to Mankin’s histologic grading
system (Mankin’s score: 0 to 14), and a cartilage destruction score
was assigned for each knee sample (n =10). Micro-Ct was performed
to see the protective effects of U0126 on subchondral bone. Cartilage
and subchondral bone tissue lysate was extracted from drug treated vs.
untreated animals and western blotting technique was applied to see
the molecular differences.
Results: pERK-1/2 was signiﬁcantly increased in the cartilage and
subchondral bone of all three OA models compared to sham conﬁrming
the pathological relevance of this signaling pathway in OA. U0126 down
regulated the pERK-1/2 expression in treatment group conﬁrming the
efﬁcacy of U0126 in inhibiting ERK at in vivo level. Furthermore, U0126
treated animal models showed signiﬁcantly reduced Mankin score (up
to 40–50%), less proteoglycan depletion, decreased expression of COL0,
RUNX2 and ADAMTS5 proteins in all three OA models compared to
untreated controls (Figure 1). OA knees showed increase in BV and BV/TV
compared to shams at week 8. The increased BV and BV/TV were partially
reversed when the animals were treated with the U0126, indicating the
therapeutic beneﬁts of U0126 on OA subchondral bone changes.
Conclusions: Together, these ﬁndings raise the possibility that ERK
blockade can be used as a therapeutic approach to inhibit OA articular
cartilage degeneration and subchondral bone changes.
Fig. 1.
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SINGLE ORAL DOSE OF (1200 MG) SACHET OF CHONDROITIN 4&6
SULFATE (CS4&6 – CHONDROSULF®) RELIEVES PAIN AND IMPROVES
FUNCTION. RESULTS OF A DOUBLE BLIND STUDY, VERSUS PLACEBO
AND AN ACTIVE TREATMENT IN KNEE OA PATIENTS
J. Reginster1, E. Tajana2. 1Univ. of Lie`ge, Lie`ge 1, Belgium; 2IBSA – Inst.
Biochimique SA, Pambio-Noranco, Switzerland
Objective: Efﬁcacy, safety and tolerability evaluation of a single oral dose,
1200mg sachet of chondroitin 4&6 sulfate (Chondrosulf® 1200) versus
placebo (superiority study) and versus 3 daily capsules of chondroitin
4&6 sulfate 400mg (Chondrosulf®400), during 91 days, in patients with
knee OA (non inferiority study).
Methods: Comparative, double-blind, randomized, multicenter study, in
parallel groups, including 353 patients of both genders, over 45 years,
with knee OA for at least 6 months. Minimum inclusion criteria was a
